Our published and preliminary studies have shown that the mouse seminal vesicle shape (svs) mutation causes prostatic branching morphogenesis and size defects as well as increased sensitivity to hormone- induced lesions that resemble early stage prostate cancer. These data suggest that the svs mutation can be used as a unique entry-point to identify a genetic pathway that regulates branching morphogenesis and tumor suppression in the prostate. We have identified a candidate svs mutation in the Fgfr2 gene that is associated with changes in alternative splicing of the Fgfr2 transcript, and changes in the activation of downstream signal transduction pathways. Fgfr2 has previously been shown to have tumor suppressor activity prostate cancer cell lines, but studies of human prostate cancer have reported conflicting results for Fgfr2. Our investigation of svs mutant mice suggests a possible explanation for the conflicts among previous studies. We have shown that alternative splicing of Fgfr2 in the prostate and seminal vesicles is much more complex than previously recognized, and changes in the spectrum of alternatively spliced Fgfr2 isoforms without changes in protein levels (as in svs mice) can have a profound impact on prostate development and cancer susceptibility. Experiments outlined in this proposal will explore the role of Fgfr2 alternative splicing in prostatic development and cancer progression. Experiments in Aim 1 will test whether the svs mutation is allelic with Fgfr2. Experiments in Aims 2 and 3 will test the hypothesis that changes in Fgfr2 alternative splicing can contribute to prostate cancer progression in mice and humans. Experiments in Aim 4 will identify gene expression changes associated with the presence/absence and alternative splicing of Fgfr2 in the prostate. These experiments will define the types of Fgfr2 mutation (isoform switching vs. loss) that promote prostate cancer progression in mice and humans. They will also define the mechanisms used by Fgfr2 to coordinate branching morphogenesis and tumor suppression in the prostate. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG024278-02
Application #
7189080
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Kohanski, Ronald A
Project Start
2006-03-01
Project End
2007-11-30
Budget Start
2007-03-01
Budget End
2007-11-30
Support Year
2
Fiscal Year
2007
Total Cost
$297,587
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Genetics
Type
Schools of Arts and Sciences
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Hammer, Kimberly D P; Alsop, James D; Buresh-Stiemke, Rita A et al. (2014) A novel method for somatic transgenesis of the mouse prostate using the Sleeping Beauty transposon system. Prostate 74:781-91
Buresh-Stiemke, Rita A; Malinowski, Rita L; Keil, Kimberly P et al. (2012) Distinct expression patterns of Sulf1 and Hs6st1 spatially regulate heparan sulfate sulfation during prostate development. Dev Dyn 241:2005-13
Buresh, Rita A; Kuslak, Sheri L; Rusch, Melissa A et al. (2010) Sulfatase 1 is an inhibitor of ductal morphogenesis with sexually dimorphic expression in the urogenital sinus. Endocrinology 151:3420-31
Rahrmann, Eric P; Collier, Lara S; Knutson, Todd P et al. (2009) Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 69:4388-97
Marker, Paul C (2008) Does prostate cancer co-opt the developmental program? Differentiation 76:736-44
Joesting, Margaret S; Cheever, Thomas R; Volzing, Katherine G et al. (2008) Secreted frizzled related protein 1 is a paracrine modulator of epithelial branching morphogenesis, proliferation, and secretory gene expression in the prostate. Dev Biol 317:161-73
Thomson, Axel A; Cunha, Gerald R; Marker, Paul C (2008) Prostate development and pathogenesis. Differentiation 76:559-64
Kuslak, Sheri L; Marker, Paul C (2007) Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction. Differentiation 75:638-51
Lange, Carol A; Gioeli, Daniel; Hammes, Stephen R et al. (2007) Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu Rev Physiol 69:171-99
Kuslak, Sheri L; Thielen, Joshua L; Marker, Paul C (2007) The mouse seminal vesicle shape mutation is allelic with Fgfr2. Development 134:557-65

Showing the most recent 10 out of 11 publications